Astellas Pharma

Astellas Pharma and Pfizer have announced an amendment to the clinical research protocol for the Phase III PROSPER trial evaluating XTANDI (enzalutamide) in patients with non-metastatic (M0) castration-resistant prostate cancer (CRPC) Read more


Abbvie, Sanofi and Novo Nordisk seens as most reputable pharma companies in the UK and industry as a whole ranked third most reputable by general public Read more


Simon Dew has been appointed to chief strategy officer and Jun Kono becomes vice president, corporate strategy & communications. Read more